Patents by Inventor Gideon Goldstein

Gideon Goldstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Potent thymopentin analogs
    Patent number: 4629723
    Abstract: Immunoregulating peptides are disclosed which are more potent than thymopentin or splenin and are useful for their effects on the immune system, especially the treatment of thymic deficiencies.
    Type: Grant
    Filed: June 27, 1984
    Date of Patent: December 16, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Gideon Goldstein, George Heavner, Daniel Kroon, Tapan Audhya
  • Hybrid cell line for producing monoclonal antibody to a human early thymocyte antigens, antibody, and methods
    Patent number: 4624925
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 10% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: October 4, 1982
    Date of Patent: November 25, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Hybrid cell line for producing monoclonal antibody to a human T cell antigen, antibody, and methods
    Patent number: 4614720
    Abstract: Hybrid cell line for production of monocloral antibody to an antigen found on essentially all normal human T cells and on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: October 4, 1982
    Date of Patent: September 30, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Bursopoietin
    Patent number: 4584284
    Abstract: A synthetic peptide which possesses the ability to specifically induce the differentiation of precursor B cells into mature B-cells capable of producing antibody.
    Type: Grant
    Filed: January 31, 1985
    Date of Patent: April 22, 1986
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Tapan Audhya, Daniel J. Kroon, George Heavner, Gideon Goldstein
  • Conformationally restricted thymopentin-like compounds
    Patent number: 4547489
    Abstract: Immunoregulating peptides are disclosed which are cyclic peptides similar to thymopentin. These peptides are useful for their effects on the immune system, especially the treatment of thymic deficiencies.
    Type: Grant
    Filed: June 11, 1984
    Date of Patent: October 15, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Gideon Goldstein, George Heavner, Tapan Audhya, Foe-Siong Tjoeng
  • Hybrid cell line for producing monoclonal antibody to human T cells
    Patent number: 4515894
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells. The hybrid is formed by fusing splenocytes from immunized Balb/cJ mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: October 4, 1982
    Date of Patent: May 7, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Hybrid cell line for producing monoclonal antibody to human helper T cells
    Patent number: 4515895
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human helper T cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: October 4, 1982
    Date of Patent: May 7, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
    Patent number: 4515893
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells and cutaneous T lymphoma cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: October 4, 1982
    Date of Patent: May 7, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Enzyme-resistant immunomodulatory peptides
    Patent number: 4505853
    Abstract: Peptides which have thymopoeitin-like or splenin-like activity combined with greatly increased resistance to degradation by enzymes. The peptides are useful for treatment of immunoregulatory disorders. Also provided are methods of treating immunoregulatory disorders and compositions used in these methods.
    Type: Grant
    Filed: November 18, 1983
    Date of Patent: March 19, 1985
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Gideon Goldstein, George Heavner, Daniel Kroon, Tapan Audhya
  • Peptides having thymopoietin-like activity
    Patent number: 4397842
    Abstract: There are disclosed peptides having the following formula:A--X--Z--Y--Bwherein A is ##STR1## X is a suitable neutral, aliphatic or aromatic amino acid residue; e.g., one selected from the group consisting of ALA, 2-Me-ALA, GLY, LEU, ILE, LYS, THR, SER, PHE, MET, D-ALA, D-LEU, D-ILE, D-LYS, D-THR, allo-THR, D-SER, D-PHE, D-MET, and SAR; Z is ##STR2## Y is GLY, SER, THR, LEU, ILE, VAL, OR SAR; B IS TYR-R', D-TYR-R', decarboxy-TYR, or ##STR3## m is 3 or 4; n is 1, 2, or 3; R''' is hydrogen, C.sub.1 -C.sub.7 alkyl, C.sub.6 -C.sub.12 aryl, or C.sub.1 -C.sub.7 alkanoyl; and R and R' are substituents which do not substantially affect the biological activity of the peptides, provided that R-ARG-LYS-ASP-VAL-TYR-R' is excluded. These peptides have the capability of inducing the differentiation of T-lymphocytes but not of complement receptor (CR.sup.+) B-lymphocytes and thus are useful in a number of therapeutic areas.
    Type: Grant
    Filed: March 30, 1981
    Date of Patent: August 9, 1983
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Gideon Goldstein, George Heavner
  • Monoclonal antibody to human helper T cells and methods of preparing same
    Patent number: 4381295
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human helper T cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: April 26, 1979
    Date of Patent: April 26, 1983
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Monoclonal antibody to a human monocyte antigen and methods of preparing same
    Patent number: 4364936
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on normal human monocytes and granulocytes. The hybrid is formed by fusing splenocytes from immunized BALB/cJ mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: January 8, 1980
    Date of Patent: December 21, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Monoclonal antibody to a human T cell antigen and methods of preparing same
    Patent number: 4364937
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on essentially all normal human T cells and on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: January 8, 1980
    Date of Patent: December 21, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
    Patent number: 4364934
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 10% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: December 4, 1979
    Date of Patent: December 21, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Monoclonal antibody to human cytotoxic and suppressor T cells and methods of preparing same
    Patent number: 4364932
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on normal human cytotoxic and suppressor T cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: October 9, 1979
    Date of Patent: December 21, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
    Patent number: 4364935
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: December 4, 1979
    Date of Patent: December 21, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Monoclonal antibody to a human thymocyte antigen and methods of preparing same
    Patent number: 4364933
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 70% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: December 4, 1979
    Date of Patent: December 21, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Monoclonal antibody to human T cells, and methods for preparing same
    Patent number: 4363799
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells. The hybrid is formed by fusing splenocytes from immunized Balb/cJ mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: March 20, 1979
    Date of Patent: December 14, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
    Patent number: 4361549
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells and cutaneous T lymphoma cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8Ul myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: April 26, 1979
    Date of Patent: November 30, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same
    Patent number: 4361550
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on normal human suppressor T cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: December 4, 1979
    Date of Patent: November 30, 1982
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein